The estimated Net Worth of Debanjan Ray is at least 398 千$ dollars as of 12 December 2018. Debanjan Ray owns over 3,000 units of CytomX Therapeutics Inc stock worth over 11,696$ and over the last 7 years Debanjan sold CTMX stock worth over 386,581$.
Debanjan has made over 18 trades of the CytomX Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Debanjan exercised 3,000 units of CTMX stock worth 4,350$ on 12 December 2018.
The largest trade Debanjan's ever made was exercising 33,000 units of CytomX Therapeutics Inc stock on 1 March 2018 worth over 39,600$. On average, Debanjan trades about 3,812 units every 25 days since 2017. As of 12 December 2018 Debanjan still owns at least 8,928 units of CytomX Therapeutics Inc stock.
You can see the complete history of Debanjan Ray stock trades at the bottom of the page.
Debanjan's mailing address filed with the SEC is C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at CytomX Therapeutics Inc have traded over 57,157,858$ worth of CytomX Therapeutics Inc stock and bought 662,000 units worth 7,876,720$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Harbor Master Investors (Ca...、James E Deerfield Mgmt L.P..... On average, CytomX Therapeutics Inc executives and independent directors trade stock every 20 days with the average trade being worth of 48,707$. The most recent stock trade was executed by Jeffrey B Landau on 20 August 2024, trading 11,250 units of CTMX stock currently worth 14,738$.
cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o
CytomX Therapeutics Inc executives and other stock owners filed with the SEC include: